Showing papers in "Clinical Microbiology and Infection in 2021"

TL;DR: The burden, epidemiology and outcomes of co-infections and superinfections occurring in hospitalized patients with coronavirus disease 2019 (COVID-19) could prove essential in defining the role of empiric antimicrobial therapy or stewardship strategies.

TL;DR: Up to 2 months after symptom onset, two thirds of adults with non-critical CO VID-19 had complaints, mainly anosmia/ageusia, dyspnea or asthenia, and a prolonged medical follow-up of patients with COVID-19 seems essential.

TL;DR: It was found that physical decline/fatigue, post-activity polypnea and alopecia were more common in females than in males, and some of these sequelae might be related to gender, age and clinical characteristics during hospitalization.

TL;DR: In this article, the authors provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for nineteen COVID-19 vaccines.

TL;DR: In this paper, the prevalence and associated factors of antibiotic prescribing in patients with SARS-CoV-2 infection were estimated in a randomized controlled trial with 30,623 patients.

TL;DR: Saliva might be an alternative specimen for the diagnosis of COVID-19 if the collection is non-invasive, and non-aerosol generating, given the simplicity of specimen collection and good diagnostic performance.

TL;DR: A meta-analysis to estimate the global and regional SARS-CoV-2 seroprevalence rates in humans, and to assess whether serop revalence associates with geographical, climatic and socio-demographic factors, suggested an association with income, human development and climate change.

TL;DR: The data suggested that patients with RT-PCR-proven COVID-19 testing negative by RAD are unlikely to be infectious, and the Panbio™ CO VID-19 Ag Rapid Test Device performed well as a POCT for early diagnosis in primary healthcare centers.

TL;DR: A review of the current knowledge of emerging SARS-CoV-2 variants, particularly those deemed VOC/Is: B.1.351, B.7, and P.1, can be found in the MEDLINE and BioRxiv databases as discussed by the authors.

TL;DR: The aim of this systematic review and meta-analysis was to assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased COVID-19 mortality compared to the standard of care.

TL;DR: Patients hospitalized with COVID-19 had a high incidence of secondary infections and early need for ICU, respiratory failure, and severe lymphopenia, were identified as risk factors for secondary infections.

TL;DR: In this article, the authors found that severe COVID-19 infection, associated with a high mortality rate, might develop in a minority of fully vaccinated individuals with multiple co-morbidities.

TL;DR: In this article, the authors conducted a multi-centre retrospective cohort study of patients in Singapore who had received a licensed mRNA vaccine and been admitted to hospital with B.1.2 infection.

TL;DR: Although adverse outcomes such as ICU admission or patient death can occur, the clinical course of COVID-19 in most women is not severe, and the infection does not significantly influence the pregnancy, therefore, CO VID-19 should not be considered as an indication for elective caesarean section.

TL;DR: In this article, the rates of antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine among kidney transplant recipients, and to identify factors associated with reduced immunogenicity were evaluated.

TL;DR: The prevalence of post-coronavirus disease 2019 (COVID-19) syndrome was 40.2% (241/599) and the presence of IgG antibodies against SARS-CoV-2 was significantly associated with the occurrence of post COVID19 syndrome (OR 2.56, 95% CI 1.48-4.38, p 0.004) as mentioned in this paper.

TL;DR: A living systematic review of the literature about the efficacy and toxicity of the IL-6 receptor antagonist, tocilizumab, in COVID-19 patients suggests that low risk of infections to high risk of adverse events is suggested to be lower than that of RCTs and observational studies at low or moderate risk of bias.

TL;DR: In 2014, the European Society of Clinical Microbiology and Infectious Diseases (ESGCD) published the first treatment guidance document for Clostridioides difficile infection (CDI) in adults.

TL;DR: In this article, the authors explored the association between female gender and long COVID syndrome, defined as persistence of physical and/or psychological symptoms for more than 4 weeks after recovery from acute COVID-19 disease.

TL;DR: Although the evidence base on bacterial infections in COVID-19 is currently limited, available evidence supports restrictive antibiotic use from an antibiotic stewardship perspective, especially upon admission, as well as other guideline recommendations on antibacterial treatment.

TL;DR: With RT-PCR assay as reference standard, NP antigen testing by FIC assay shows high specificity and relative high sensitivity in SARS-CoV-2 diagnosis in the early phase of infection.

TL;DR: In this paper, a case definition of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proposed, including a microbiologically confirmed definition, as well as clinical and epidemiological ones.

TL;DR: In this article, the Panbio™ COVID-19 Ag Rapid Test Device (Abbott Diagnostics, Jena, Germany) was evaluated for detecting SARS-CoV-2-infected asymptomatic individuals.

TL;DR: The immunogenicity and safety of the Pfizer-BioNTech BNT162b2 mRNA vaccine in people living with human immunodeficiency virus type 1 (PLWH) are unknown as mentioned in this paper.

TL;DR: IPA is a relatively frequent complication in severe COVID-19 patients responsible for increased mortality and Azithromycin, known to have immunomodulatory properties, may contribute to increase CO VID-19 patient susceptibility to IPA.

TL;DR: Tocilizumab might be useful in COVID-19 patients with hyperinflammatory state and should be prioritized for randomized trials, according to clinical and laboratory parameters.

TL;DR: In this article, the persistence of humoral immunity for up to 6 months in a cohort of hospital employees with mild coronavirus disease 2019 (COVID-19) was evaluated longitudinally.

TL;DR: Immune response to SARS-CoV-2 peptides in a whole-blood assay is associated to COVID-19 and it is characterized by both Th1 and Th2 profile, which may be useful for developing new T-cell based diagnostic tests for disease and vaccine settings.

TL;DR: Clinical spectrum and outcomes of neurological manifestations associated with SARS-CoV-2 infection were broad and heterogeneous, suggesting different underlying pathogenic processes.

TL;DR: Wang et al. as discussed by the authors presented a living review aiming to critically appraise available data about secondary attack rates from people with asymptomatic, pre-symptomatic and symptomatic SARS-CoV-2 infection.